These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 20363564)
1. Molecular predictive and prognostic markers in colon cancer. Winder T; Lenz HJ Cancer Treat Rev; 2010 Nov; 36(7):550-6. PubMed ID: 20363564 [TBL] [Abstract][Full Text] [Related]
2. Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer. Grem JL Semin Oncol; 2005 Feb; 32(1):120-7. PubMed ID: 15726514 [TBL] [Abstract][Full Text] [Related]
3. [The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer]. Laurent-Puig P; Lièvre A; Ducreux M; Loriot MA Bull Cancer; 2008 Oct; 95(10):935-42. PubMed ID: 19004723 [TBL] [Abstract][Full Text] [Related]
4. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090 [TBL] [Abstract][Full Text] [Related]
5. Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer. Allen WL; Johnston PG Pharmacogenomics; 2005 Sep; 6(6):603-14. PubMed ID: 16143000 [TBL] [Abstract][Full Text] [Related]
6. Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer. Bhushan S; McLeod H; Walko CM Clin Colorectal Cancer; 2009 Jan; 8(1):15-21. PubMed ID: 19203892 [TBL] [Abstract][Full Text] [Related]
7. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634 [TBL] [Abstract][Full Text] [Related]
8. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer]. Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867 [TBL] [Abstract][Full Text] [Related]
9. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Koopman M; Venderbosch S; Nagtegaal ID; van Krieken JH; Punt CJ Eur J Cancer; 2009 Jul; 45(11):1935-49. PubMed ID: 19473832 [TBL] [Abstract][Full Text] [Related]
10. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Ichikawa W; Uetake H; Shirota Y; Yamada H; Nishi N; Nihei Z; Sugihara K; Hirayama R Clin Cancer Res; 2003 Feb; 9(2):786-91. PubMed ID: 12576451 [TBL] [Abstract][Full Text] [Related]
11. Biological prognostic and predictive factors in lung cancer. Rossi A; Galetta D; Gridelli C Oncology; 2009; 77 Suppl 1():90-6. PubMed ID: 20130436 [TBL] [Abstract][Full Text] [Related]
12. Biomarkers for personalized oncology: recent advances and future challenges. Kalia M Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140 [TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Tan BR; McLeod HL Semin Oncol; 2005 Feb; 32(1):113-9. PubMed ID: 15726513 [TBL] [Abstract][Full Text] [Related]
14. Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer. Kleist B; Kempa M; Meurer T; Poetsch M J Clin Pathol; 2016 Mar; 69(3):204-8. PubMed ID: 26281864 [TBL] [Abstract][Full Text] [Related]
15. Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab. Budai B; Komlósi V; Adleff V; Pap É; Réti A; Nagy T; Kralovánszky J; Láng I; Hitre E Pharmacogenet Genomics; 2012 Jan; 22(1):69-72. PubMed ID: 22044939 [TBL] [Abstract][Full Text] [Related]
16. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Koopman M; Venderbosch S; van Tinteren H; Ligtenberg MJ; Nagtegaal I; Van Krieken JH; Punt CJ Eur J Cancer; 2009 Jul; 45(11):1999-2006. PubMed ID: 19457654 [TBL] [Abstract][Full Text] [Related]
17. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients. Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794 [TBL] [Abstract][Full Text] [Related]
18. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX. Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872 [TBL] [Abstract][Full Text] [Related]
19. The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions. Schmoll HJ Semin Oncol; 2002 Oct; 29(5 Suppl 15):34-9. PubMed ID: 12422306 [TBL] [Abstract][Full Text] [Related]
20. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. Locker GY; Hamilton S; Harris J; Jessup JM; Kemeny N; Macdonald JS; Somerfield MR; Hayes DF; Bast RC; J Clin Oncol; 2006 Nov; 24(33):5313-27. PubMed ID: 17060676 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]